论文部分内容阅读
目的观察剂量密集化疗在腋窝淋巴结阳性乳腺癌辅助化疗中的疗效和不良反应。方法选取56例腋窝淋巴结转移阳性的乳腺癌术后患者,给予表阿霉素联合环磷酰胺序贯紫杉醇的两周剂量密集方案辅助化疗。结果 56例中,54例完成全部化疗,2例因毒性不能耐受更换为三周方案,56例患者均可评价不良反应,3-4级不良反应主要有中性粒细胞下降、血小板减少、贫血、神经毒性等,1例患者出现中性粒细胞下降性发热,无治疗相关性死亡发生。中位随访时间30个月,1年和2年无病生存率分别为96.4%和87.5%,1年和2年总生存率分别为100%和98.2%。结论表阿霉素联合环磷酰胺序贯紫杉醇的两周剂量密集方案作为腋窝淋巴结阳性乳腺癌患者的辅助化疗具有较好的疗效和安全性。
Objective To observe the efficacy and adverse reactions of dose-intensive chemotherapy in adjuvant chemotherapy of axillary lymph node-positive breast cancer. Methods Fifty-six patients with breast cancer with positive axillary lymph node metastasis were enrolled in this study. Two weeks intensive dose chemotherapy with epirubicin and cyclophosphamide sequential paclitaxel was given. Results Among the 56 cases, 54 cases completed chemotherapy, 2 cases were unable to tolerate to be replaced by three weeks regimen, 56 cases were able to evaluate adverse reactions, Grade 3-4 adverse reactions were mainly neutropenia, thrombocytopenia, Anemia, neurotoxicity, etc. One patient had neutropenia fever and no treatment-related death occurred. The median follow-up time was 30 months. The 1-year and 2-year disease-free survival rates were 96.4% and 87.5%, respectively. The 1-year and 2-year overall survival rates were 100% and 98.2%, respectively. Conclusion Epirubicin combined with cyclophosphamide sequential paclitaxel two weeks dose-intensive regimen as axillary lymph node-positive breast cancer patients with adjuvant chemotherapy has good efficacy and safety.